Signios Biosciences announced its rebranding from its previous identity as the US based research division of MedGenome Inc. This milestone marks a new era, better positioning the brand in the US on its mission of long-term partnership with researchers to accelerate precision medicine and drug discovery.
With a focus on scientific collaboration and breakthrough discovery, Signios Bio offers an integrated end-to-end suite of multiomic technologies, including genomics, transcriptomics, proteomics, epigenomics, metabolomics, microbiomics, and spatial biology—all powered by a proprietary, AI-driven bioinformatics platform. This comprehensive capability empowers pharmaceutical companies, biotech firms, and academic institutions to decode complex disease biology, identify novel biomarkers, and drive forward targeted therapies and diagnostics.
“The challenge today is about how best to pull insights from biological information and organize it in a way that accelerates medical insights,” said Felix Olale, MD, PhD, CEO and President of Signios Bio. “Through our ‘The Cure is in the Code’ approach, we help our partners extract meaning from complexity by revealing the key biological signals that drive disease—and do it in a way that’s inclusive, precise, and globally relevant.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!